Daniel R Wahl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2344041/publications.pdf

Version: 2024-02-01

41 papers 1,724 citations

471509 17 h-index 330143 37 g-index

44 all docs

44 docs citations

times ranked

44

2606 citing authors

#	Article	IF	CITATIONS
1	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer Discovery, 2019, 9, 1673-1685.	9.4	566
2	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Research, 2019, 79, 3940-3951.	0.9	154
3	PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Molecular Cancer Research, 2018, 16, 222-232.	3.4	108
4	Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nature Communications, 2020, 11, 3811.	12.8	103
5	Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. The Lancet Digital Health, 2022, 4, e8-e17.	12.3	91
6	Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance. Cancers, 2019, 11, 1231.	3.7	90
7	Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Cancer Cell, 2020, 38, 334-349.e9.	16.8	87
8	Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. Cancer Research, 2017, 77, 960-970.	0.9	78
9	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. Npj Breast Cancer, 2017, 3, 29.	5.2	45
10	Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. Radiology, 2017, 283, 460-468.	7.3	36
11	Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy. Cancer & Metabolism, 2020, 8, 1.	5.0	34
12	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. Frontiers in Endocrinology, 2020, 11, 35.	3.5	24
13	Stereotactic Radiosurgery for Brain Arteriovenous Malformations: Evaluation of Obliteration and Review of Associated Predictors. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104863.	1.6	23
14	A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 792-803.	0.8	23
15	Integrating chemoradiation and molecularly targeted therapy. Advanced Drug Delivery Reviews, 2017, 109, 74-83.	13.7	22
16	Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination–Proficient Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 263-273.	4.1	22
17	Brainstem Low-Grade Gliomas in Children—Excellent Outcomes With Multimodality Therapy. Journal of Child Neurology, 2017, 32, 194-203.	1.4	21
18	Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas. Science Translational Medicine, 2021, 13, eabf7860.	12.4	18

#	Article	IF	CITATIONS
19	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro-Oncology, 2019, 21, 1141-1149.	1.2	17
20	Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Molecular Cancer Therapeutics, 2020, 19, 2163-2174.	4.1	17
21	MRNIP condensates promote DNA double-strand break sensing and end resection. Nature Communications, 2022, 13, 2638.	12.8	17
22	Translation of Targeted Radiation Sensitizers into Clinical Trials. Seminars in Radiation Oncology, 2016, 26, 261-270.	2.2	16
23	Combining Perfusion and High B-value Diffusion MRI to Inform Prognosis and Predict Failure Patterns in Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 757-764.	0.8	16
24	Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma. Neuro-Oncology, 2021, 23, 1537-1546.	1.2	12
25	2â∈Hydoxyglutarate: D/Riving Pathology in gLiomaS. Brain Pathology, 2015, 25, 760-768.	4.1	11
26	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. International Journal of Radiation Oncology Biology Physics, 2017, 98, 726-732.	0.8	11
27	Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2019, 143, 313-319.	2.9	11
28	Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. Npj Genomic Medicine, 2021, 6, 76.	3.8	10
29	No Sugar Added: A New Strategy to Inhibit Glioblastoma Receptor Tyrosine Kinases. Clinical Cancer Research, 2019, 25, 455-456.	7.0	9
30	Clinical Targeting of Altered Metabolism in High-Grade Glioma. Cancer Journal (Sudbury, Mass), 2021, 27, 386-394.	2.0	6
31	Genomic-adjusted radiation dose. Lancet Oncology, The, 2017, 18, e127.	10.7	5
32	Interactions between Radiation and One-Carbon Metabolism. International Journal of Molecular Sciences, 2022, 23, 1919.	4.1	4
33	Running the Light: Nucleotide Metabolism Drives Bypass of Senescence in Cancer. Trends in Biochemical Sciences, 2019, 44, 991-993.	7.5	3
34	Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma. Molecular and Cellular Oncology, 2020, 7, 1834902.	0.7	3
35	Targeting Tumor Metabolism to Overcome Radioresistance. Cancer Drug Discovery and Development, 2020, , 219-263.	0.4	2
36	A Complementary Strategy to Mitigate Radiation-Induced Cognitive Decline. Cancer Research, 2021, 81, 1635-1636.	0.9	2

#	Article	IF	CITATIONS
37	Survival Prediction Analysis in Glioblastoma With Diffusion Kurtosis Imaging. Frontiers in Oncology, 2021, 11, 690036.	2.8	2
38	Efficacy and Toxicity with Radiation Field Designs and Concurrent Temozolomide for CNS Lymphoma. Neuro-Oncology Practice, 0, , .	1.6	1
39	Evaluation of liver toxicity using Child-Pugh, MELD, and MELD-Na following stereotactic body radiation therapy (SBRT) of hepatocellular carcinomas Journal of Clinical Oncology, 2015, 33, 365-365.	1.6	O
40	Association between equivalent uniform dose (EUD) and rates of local progression in liver tumors treated with stereotactic body radiation therapy (SBRT) Journal of Clinical Oncology, 2015, 33, 380-380.	1.6	0
41	Targeting Noncanonical Regulators of the DNA Damage Response to Selectively Overcome Cancer Radiation Resistance. Seminars in Radiation Oncology, 2022, 32, 64-75.	2.2	0